Infex Therapeutics announces positive Phase IIa results for RESP-X in non-cystic fibrosis bronchiectasis patients colonised with Pseudomonas aeruginosa
Infex Therapeutics, a leading anti-infectives specialist, today announced positive results from its Phase IIa dose-ranging study evaluating…
Infex Therapeutics secures £4.3 million funding to advance anti-infective pipeline targeting drug-resistant infections
Investment led by Jon Moulton supports progression of clinical and preclinical programmes addressing critical-priority pathogens Infex to…
World AMR Awareness Week 2025
This World AMR Awareness Week, we're proud to be celebrating our collaboration with iiCON, the Infection Innovation Consortium.
UK Government investment is vital to combat AMR
As the world wakes to the reality of the crisis posed by antimicrobial resistance (AMR), it’s clear that decisions taken today will have…
Infex agrees collaboration with Asian clinical trials network, ADVANCE-ID
Memorandum of Understanding signed to investigate hospital-acquired drug-resistant infections in Asia
Infex signs exclusive license agreement with Venus Remedies Ltd to advance MET-X through clinical development and commercialisation in India
Infex Therapeutics, a leading anti-infectives specialist, announces that it has signed an exclusive license agreement for the Indian market…
Infex and Justus-Liebig-University Giessen awarded £1 million grant from PACE
Grant to develop first-in-class antimicrobial drug targeting multi-drug-resistant bacteria
First NCFB patient dosed in Phase IIa study of RESP-X
Potential first-in-class anti-virulence antibody drug to reduce the frequency of debilitating exacerbations in respiratory patients with…
Infex invites you to Alderley Park’s 10th Anniversary SciTech Extravaganza
Come and join us in Glasshouse at Alderley Park for an interactive and inspiring day of science and technology fun, in collaboration with…
Infex to present RESP-X Phase I data at ERS Congress
RESP-X is a potential blockbuster anti-virulence antibody drug to reduce the frequency of debilitating exacerbations in respiratory…